Evidence map›Paper›PMID 42163062›Full record

ReviewHuman vaccines & immunotherapeutics2026

Tebentafusp (IMCgp100), a first in class immune-mobilizing monoclonal T-cell receptors against cancer (ImmTAC) for HLA-A*02:01 positive uveal melanoma: Product review.

Jonathan E Cohen, Inderjit Mehmi, Mordechai Avner, Justin Moyers, Omid Hamid

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Human vaccines & immunotherapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Jonathan E CohenSharett Institute of Oncology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel.ORCID 0000-0001-8120-3827
Inderjit MehmiThe Angeles Clinic & Research Institute, A Cedars-Sinai Affiliate, Los Angeles, CA, USA.
Mordechai AvnerSharett Institute of Oncology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel.
Justin MoyersThe Angeles Clinic & Research Institute, A Cedars-Sinai Affiliate, Los Angeles, CA, USA.
Omid HamidThe Angeles Clinic & Research Institute, A Cedars-Sinai Affiliate, Los Angeles, CA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tebentafusp (IMCgp100, Kimmtrak) is a first-in-class Immune mobilizing monoclonal T-cell receptors against cancer (ImmTAC). ImmTAC are fusion proteins comprising an affinity-enhanced soluble T-cell receptor (TCR) against a specific peptide-HLA complex and an anti-CD3 single-chain variable fragment (scFv). Tebentafusp binds gp100

Indexed as

Antibodies, Monoclonalgp100 Melanoma AntigenHLA-A2 AntigenImmunotherapyMelanomaReceptors, Antigen, T-CellUveal NeoplasmsHumansRecombinant Fusion ProteinsUveal MelanomaAntibodies, Monoclonalgp100 Melanoma AntigenHLA-A*02:01 antigenHLA-A2 AntigenReceptors, Antigen, T-CellRecombinant Fusion Proteinscancer immunotherapyhuman leukocyte antigen (HLA)Immune-mobilizing monoclonal T-cell receptors against cancer (ImmTAC)T-cell receptor (TCR)Uveal melanoma

Identifiers

PMID42163062
PMCPMC13196628

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.